AIT-101
- Generic Name
- AIT-101
An Open-Label, Expanded Access Protocol of LAM-002A in C9ORF72-Associated Frontotemporal Dementia (FTD)
- Conditions
- Frontotemporal Dementia
- First Posted Date
- 2022-08-02
- Last Posted Date
- 2022-08-02
- Lead Sponsor
- OrphAI Therapeutics
- Registration Number
- NCT05483322
Study of Safety, Tolerability, and Biological Activity of LAM-002A in C9ORF72-Associated Amyotrophic Lateral Sclerosis
Phase 2
Active, not recruiting
- Conditions
- Amyotrophic Lateral SclerosisALS
- Interventions
- Other: Placebo
- First Posted Date
- 2021-12-20
- Last Posted Date
- 2024-08-20
- Lead Sponsor
- OrphAI Therapeutics
- Target Recruit Count
- 14
- Registration Number
- NCT05163886
- Locations
- 🇺🇸
Johns Hopkins University School of Medicine, Baltimore, Maryland, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States
A Phase I Dose Escalation Study of the Safety and Pharmacokinetics of LAM-002A In Patients With Non-Hodgkin's Lymphoma
Phase 1
Completed
- Conditions
- Lymphoma, Non-Hodgkin; Leukemia, Chronic Lymphocytic
- Interventions
- First Posted Date
- 2015-11-03
- Last Posted Date
- 2024-08-22
- Lead Sponsor
- OrphAI Therapeutics
- Target Recruit Count
- 62
- Registration Number
- NCT02594384
- Locations
- 🇺🇸
Clearview Cancer Institute, Huntsville, Alabama, United States
🇺🇸Winship Cancer Institute at Emory University, Atlanta, Georgia, United States
🇺🇸Horizon Oncology Research, Inc., Lafayette, Indiana, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath